Related Experiment Video
Updated: Nov 16, 2025
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
Jingjing Qu1, Quanhui Mei2, Li Liu3
1Department of Respiratory Disease, Thoracic Disease Centre, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, PR China.
Abstract:
The use of programmed cell-death protein 1 (PD-1)/programmed cell-death ligand 1 (PD-L1) inhibitors is the standard therapy for the first-line or second-line treatment of patients with non-small-cell lung cancer (NSCLC). In contrast to current traditional treatments such as chemotherapy or radiotherapy, anti-PD-1 and anti-PD-L1 treatments can directly attenuate tumour-mediated exhaustion and effectively modulate the host anti-tumour immune response in vivo. In addition, compared with traditional therapy, PD-1/PD-L1 inhibitor monotherapy can significantly prolong survival without obvious side effects in the treatment of advanced NSCLC. Ideally, several biomarkers could be used to monitor the safety and effectiveness of anti-PD-1 and anti-PD-L1 treatments; however, the current lack of optimal prognostic markers remains a widespread limitation and challenge for further clinical applications, as does the possibility of immune-related adverse events and drug resistance. In this review, we aimed to summarise the latest progress in anti-PD-1/anti-PD-L1 treatment of advanced NSCLC, worldwide, including in China. An exploration of underlying biomarker identification and future challenges will be discussed in this article to facilitate translational studies in cancer immunotherapy.
Insights
Programmed cell-death protein 1 (PD-1)/PD-1 ligand 1 (PD-L1) inhibitors offer improved survival for advanced non-small-cell lung cancer (NSCLC). Further research into biomarkers is crucial for optimizing immunotherapy efficacy and managing resistance.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- Programmed cell-death protein 1 (PD-1)/PD-1 ligand 1 (PD-L1) inhibitors are standard treatments for non-small-cell lung cancer (NSCLC).
- These immunotherapies modulate the host immune response against tumors, offering advantages over traditional chemotherapy and radiotherapy.
- PD-1/PD-L1 inhibitor monotherapy has shown prolonged survival with fewer side effects in advanced NSCLC.
Purpose of the Study:
- To review the latest advancements in PD-1/PD-L1 inhibitor treatment for advanced NSCLC globally, including China.
- To explore the identification of biomarkers for monitoring treatment safety and efficacy.
- To discuss future challenges in cancer immunotherapy for NSCLC.
Main Methods:
- Literature review of recent studies on PD-1/PD-L1 inhibitors in advanced NSCLC.
- Analysis of biomarker research related to immunotherapy response and resistance.
- Discussion of clinical application limitations and future research directions.
Main Results:
- PD-1/PD-L1 inhibitors represent a significant therapeutic advance in advanced NSCLC.
- Lack of optimal prognostic biomarkers is a major limitation for current immunotherapy.
- Immune-related adverse events and drug resistance are key challenges.
Conclusions:
- PD-1/PD-L1 inhibitors have transformed NSCLC treatment, offering improved survival and safety profiles.
- Development of reliable biomarkers is essential for personalized immunotherapy and overcoming resistance.
- Continued research is vital to enhance the clinical application and translational studies of cancer immunotherapy.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...